Document is current
Any future updates will be listed below
-
Authors
Martin, Elise
Chichua, Mariam
Chiodi, Camila Kelly
Zyumbileva, Petya
Lapidari, Pietro
Pagliuca, Martina
Gillanders, Emma
Barbier, Aude
Bertaut, Aurélie
Boinon, Diane
Martin, Anne-Laure
Everhard, Sibille
Golli, Liliane
Jouannaud, Christelle
Kaderbhai, Courèche
Mery, Benoîte
Rigal, Olivier
Franzoi, Maria Alice
Vaz-Luis, Ines
Di Meglio, Antonio https://orcid.org/0000-0002-0233-3189
-
Funding
Funding for this research was provided by:
Ruban Rose Foundation (Quality of Life Grant)
Agence Nationale de la Recherche (CANTO - ANR-10-COHO-0004)
National Cancer Institute of France (SHS-E-SP-2021 N. 15864)
Conquer Cancer, the American Society of Clinical Oncology (ASCO) Foundation and Rising Tide Foundation for Clinical Cancer Research (Career Pathway Grant in Symptom Management)
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 26 January 2026
First Online: 11 February 2026
Declarations
:
: MAF: Research funding from Resilience Care (institutional) and Gilead Sciences (institutional); speaker honoraria from Novartis. IVL: Speaker honoraria from Amgen, AstraZeneca, Pfizer/Edimark, Novartis, and Sandoz (institutional); writing engagement from Pfizer/Edimark (institutional); research funding from Resilience Care (institutional); travel support from Novartis. MP: Research funding from Gilead (institutional); travel and accommodation support from Gilead and Ipsen. CJ: Advisory board member; personal financial interests with Daiichi Sankyo and AstraZeneca. ADM, EM, PZ, PL, BM, EG, AB, MC, CC, DB, CK, and OR declare no competing interests.
